Dallas, Texas — According to state and local economic development sources Taysha plans to invest $1,100,000.00 to build out 36,285 square feet of new space in Dallas. The company plans to occupy the new space at 3000 Pegasus Park Suite 1430 in Dallas, on or about May 1, 2021. According to the company website We want to do more than just treat monogenic CNS disease. We want to eradicate it. We are singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), both in rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern) to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we have created a powerful engine to develop transformative therapies with the potential to dramatically improve patients’ lives.

To learn more about Taysha, visit http://tayshagtx.com/

Company Contact:
RA Session, Chief Executive Officer
https://www.linkedin.com/in/r-a-session-ii-bba8178/
214-612-0000

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved